<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861861</url>
  </required_header>
  <id_info>
    <org_study_id>Kumamoto-746</org_study_id>
    <nct_id>NCT00861861</nct_id>
  </id_info>
  <brief_title>Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)</brief_title>
  <acronym>COMPACT-CAD</acronym>
  <official_title>Comparison of Pitavastatin With Atorvastatin in Increasing HDL-C and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kumamoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kumamoto University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of pitavastatin and atorvastatin on
      adiponectin percentage change in patients with hypercholesteremia comorbid stable CAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficiency of lipid lowering therapy was already proven by the clinical trials of
      statins. According to these results, the target value of LDL-C is recommended under 100mg/dL
      in the Japan Atherosclerosis Society Guidelines. However, the efficiency of intensive therapy
      to lower LDL-C more than 100mg/dL has not been proven yet.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL-cholesterol (HDL-C); Adiponectin; High-Molecular- Weight Adiponectin(HMW Adiponectin)</measure>
    <time_frame>start, 6 months, 12 months, 30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TC; LDL-C; HDL-C; HDL2-C; HDL3-C; TG; smalldenseLDL; MDA-LDL; FPG; HbA1c; Cr; RLP-C; apoA-I; apoB; apoC-Ⅱ; apoC-Ⅲ</measure>
    <time_frame>start, 6 months, 12 months, 30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pitavastatin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>comparison of two drugs in increasing HDL-C and adiponectin</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>comparison of two drugs in increasing HDL-C and adiponectin</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with dyslipidemia as defined by any of the parameters:

               -  HDL-C &lt; 50 mg/dL

               -  LDL-C ≥ 140 mg/dL

               -  LDL-C ≥ 100 mg/dL and cholesterol-lowering treatment is necessary in accordance
                  with the investigator's judgement

          -  Patients who passed three months or more after acute myocardial infarction

          -  Patients who passed one month or more after unstable angina

          -  Patients who passed one month or more after PCI

          -  Patients with written consent by their own volition after being provided sufficient
             explanation for the participation into this clinical trial

        Exclusion Criteria:

          -  Patients with any allergy to pitavastatin or atorvastatin

          -  Patients with familial hypercholesterolemia

          -  Patients receiving pitavastatin

          -  Patients with severe hypertension

          -  Patients with renal disorders or undergoing dialysis

          -  Patients with hepatobiliary disorders

          -  Patients with hepatobiliary disorders

          -  Patients with family history of hypothyroidism or muscular dystrophy

          -  Patients with history of drug-induced hepatic disorder

          -  Drug abuser or dipsomaniac

          -  Patients with cardiogenic shock.

          -  Patients who hopes for pregnancy during this study

          -  Contraindications, Relative Contraindications, Absolute Contraindications for
             Coadministration and Relative Contraindications for Coadministration for pitavastatin
             or atorvastatin

          -  Patients who are ineligible in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisao Ogawa, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kumamoto University Graduate School of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kumamoto University Graduate School of Medical Sciences Department of Cardiocascular Medicine</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kumamoto University</investigator_affiliation>
    <investigator_full_name>Hisao Ogawa</investigator_full_name>
    <investigator_title>Kumamoto University</investigator_title>
  </responsible_party>
  <keyword>Pitavastatin</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>CAD</keyword>
  <keyword>HDL-C</keyword>
  <keyword>Adiponectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

